The FDA will revise existing pre-submission draft guidance for ANDAs in light of the passage of the FDA Reauthorization Act of 2017.
Source: Drug Industry Daily
The FDA will revise existing pre-submission draft guidance for ANDAs in light of the passage of the FDA Reauthorization Act of 2017.
Source: Drug Industry Daily